| Literature DB >> 34934839 |
Abstract
Ecological, sensitive, fast and economic approaches are the main aspects in quality control of pharmaceutical products. Elagolix (ELG) is an orally non-peptidic GnRH antagonist, recently approved drug by Food and drug administration in 2018 for treatment of pain associated with endometriosis. A green, and sensitive method was developed and validated for determination of ELG based on micellar spectrofluorometric approach. Many factors were studied to enhance the fluorescence intensity of ELG and the highest sensitivity was obtained upon using 1% Sodium dodecyl sulphate (SDS) at 438 nm after excitation at 270 nm. A linear relationship was obtained over a range of 50-1000 ng mL-1 between ELG concentration and corresponding fluorescence intensity. The developed method was validated according to ICH guidelines and successfully applied for testing the content uniformity and determination of ELG in pharmaceutical dosage forms with percentage recovery 99.31 ± 1.98. Furthermore, the capability of the method due to its high sensitivity to determine ELG in human plasma with percentage recoveries in a range of 98.54-100.46. The greenness of the method was investigated using three different approaches; Analytical Procedure Index (GAPI), Analytical Eco-Scale and Analytical Greenness Metric (AGREE).Entities:
Keywords: Content uniformity; Elagolix; Greenness assessment; Human plasma; Spectrofluorimetry
Year: 2021 PMID: 34934839 PMCID: PMC8654795 DOI: 10.1016/j.heliyon.2021.e08521
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Chemical structure of ELG.
Figure 2Excitation (a’, b’) and emission spectra (a,b) of ELG in SDS system.
Figure 3(a) Effect of different solvents on the fluorescence intensity of ELG. (b) Effect of different organized media on the fluorescence intensity of ELG.
Figure 4(a) Effect of % of SDS on the fluorescence of ELG. (b) Effect of volume of SDS on the fluorescence of ELG. (c) Effect of pH on the fluorescence of ELG in SDS system.
Analytical parameters of the proposed spectrofluorometric method for determination of ELG.
| Parameter | Spectrofluorometric Method |
|---|---|
| λex | 270 |
| λem | 438 |
| Regression equation | |
| Range (ng.mL−1) | 50–1000 |
| Correlation coefficient (r) | 0.9994 |
| Slope | 0.32 |
| Intercept | 166.49 |
| S.D of slope | 0.002 |
| S.D of intercept | 1.60 |
| LOD(ng.mL−1) | 16.50 |
| LOQ (ng.mL−1) | 50.0 |
| Repeatability (Intraday) | |
| QCL (200 ng mL−1) | 1.20 % |
| QCM (500 ng mL−1) | 0.48 % |
| QCH (800 ng mL−1) | 0.29 % |
| Intermediate precision (Inter-day) | |
| QCL (200 ng mL−1) | 0.18 % |
| QCM (500 ng mL−1) | 0.86 % |
| QCH (800 ng mL−1) | 0.29 % |
| QCL (200 ng mL−1) | 99.86 ± 0.88 |
| QCM (500 ng mL−1) | 98.72 ± 0.26 |
| QCH (800 ng mL−1) | 101.07 ± 0.16 |
RSD: relative standard deviation.
Expressed mean of three replicates.
Application of the proposed method for determination of ELG in pharmaceutical dosage form and application of standard addition technique.
| Dosage form | Claimed (ng.mL−1) | % Found (Mean ± SD) | Standard addition technique | |
|---|---|---|---|---|
| Pure added (ng.mL−1) | % Recovery | |||
| Orlessa ®tablets (contains150 mg elagolix) | 400 | 99.31 ± 1.98 | 100 | 101.23 ± 0.18 |
| 400 | 101.74 ± 0.50 | |||
| 600 | 101.12 ± 0.51 | |||
Average of three determinations.
Application of the proposed method for determination of content uniformity of ELG in pharmaceutical dosage form.
| Tablet number | % Recovery of the content claimed |
|---|---|
| 1 | 99.73 |
| 2 | 99.13 |
| 3 | 98.67 |
| 4 | 99.4 |
| 5 | 98.57 |
| 6 | 99.83 |
| 7 | 100.20 |
| 8 | 100.03 |
| 9 | 99.03 |
| 10 | 99.01 |
| Mean | 99.36 |
| SD | 0.57 |
| RSD | 0.57 |
| Acceptance value (AV) | 1.37 |
| Max. allowed AV (L1) | 15 |
The values is the mean of three determinations.
Application of the proposed method for determination of studied drug in spiked human plasma.
| Amount taken (ng.mL−1) | Amount found | % Recovery± SD | %CV |
|---|---|---|---|
| 50 | 49.27 ± 0.51 | 98.54 ± 0.91 | 0.93 |
| 200 | 99.64 ± 1.37 | 99.64 ± 1.37 | 1.37 |
| 500 | 496.59 ± 2.68 | 99.32 ± 0.54 | 0.54 |
| 800 | 803.66 ± 3.48 | 100.46 ± 0.43 | 0.43 |
Average of five determinations.
Coefficient of variation.
Figure 5(a) GAPI pictogram for evaluation of the proposed method greenness. (b) Analytical greenness metric for evaluation of the proposed method greenness.
The penalty points of the proposed method according to the analytical Eco-Scale.
| Value | Penalty points | |
|---|---|---|
| Reagents | ||
| Water | <10 mL | 0 |
| SDS | <10 mL | 0 |
| Acetonitrile | <10 mL | 4 |
| Instrument | ||
| Spectrofluorometry | ≤0.1 kWh | 0 |
| Occupational hazard | Analytical process hermetization | 0 |
| Waste | ||
| Waste amount | 1–10 mL | 3 |
| Waste Treatment | No treatment | 3 |
| Total penalty points | ||
| Analytical eco-scale total score | ||